Gandara DR, Von Pawel J, Sullivan RN, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001).
Veel nieuwe behandelopties verwacht bij behandeling urotheelcelcarcinoom
nov 2019 | Immuuntherapie, Uro-oncologie